Tarantini G, et al. - Researchers pooled patients from three large, prospective studies to compare Absorb bioresorbable vascular scaffolds (BVS) to a 2nd-generation metallic everolimus-eluting stents (EES) in respect to outcomes in patients with small vessel disease (SVD). They used the Italian RAI and the MAASSTAD-Absorb registries to identify SVD patients (reference vessel diameter ≤2.75 mm by QCA) treated with Absorb BVS. The COMPARE II Trial was used as the source of EES controls. In this propensity-matched analysis using several clinical and angiographic variables with up to 2 years follow-up demonstrated the comparable incidence of composite device-related events between BVS and EES. However, the BVS group had higher rates of stent thrombosis.